Clinical Trial Update: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Revumenib in combination with azacitidine and venetoclax for adults with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Kmt2a Rearrangement
• Acute Myeloid Leukemia with Npm1 Mutation

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Revumenib (revumenib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland | Conditions: Acute Myeloid Leukemia, Adult | Phase 3 | Status: RECRUITING